S&P 500   5,130.80 (-0.12%)
DOW   38,980.11 (-0.27%)
QQQ   445.22 (-0.09%)
AAPL   175.28 (-2.44%)
MSFT   415.51 (+0.00%)
META   499.65 (-0.53%)
GOOGL   133.71 (-2.50%)
AMZN   178.15 (-0.04%)
TSLA   189.13 (-6.67%)
NVDA   864.46 (+5.06%)
NIO   5.43 (-6.06%)
AMD   208.48 (+2.88%)
BABA   72.07 (-3.42%)
T   16.77 (-1.24%)
F   12.81 (+2.89%)
MU   96.73 (+1.66%)
CGC   3.05 (-4.98%)
GE   160.91 (+1.42%)
DIS   113.97 (+1.80%)
AMC   4.34 (-0.46%)
PFE   25.80 (-2.97%)
PYPL   60.12 (-0.69%)
XOM   104.43 (-1.33%)
S&P 500   5,130.80 (-0.12%)
DOW   38,980.11 (-0.27%)
QQQ   445.22 (-0.09%)
AAPL   175.28 (-2.44%)
MSFT   415.51 (+0.00%)
META   499.65 (-0.53%)
GOOGL   133.71 (-2.50%)
AMZN   178.15 (-0.04%)
TSLA   189.13 (-6.67%)
NVDA   864.46 (+5.06%)
NIO   5.43 (-6.06%)
AMD   208.48 (+2.88%)
BABA   72.07 (-3.42%)
T   16.77 (-1.24%)
F   12.81 (+2.89%)
MU   96.73 (+1.66%)
CGC   3.05 (-4.98%)
GE   160.91 (+1.42%)
DIS   113.97 (+1.80%)
AMC   4.34 (-0.46%)
PFE   25.80 (-2.97%)
PYPL   60.12 (-0.69%)
XOM   104.43 (-1.33%)
S&P 500   5,130.80 (-0.12%)
DOW   38,980.11 (-0.27%)
QQQ   445.22 (-0.09%)
AAPL   175.28 (-2.44%)
MSFT   415.51 (+0.00%)
META   499.65 (-0.53%)
GOOGL   133.71 (-2.50%)
AMZN   178.15 (-0.04%)
TSLA   189.13 (-6.67%)
NVDA   864.46 (+5.06%)
NIO   5.43 (-6.06%)
AMD   208.48 (+2.88%)
BABA   72.07 (-3.42%)
T   16.77 (-1.24%)
F   12.81 (+2.89%)
MU   96.73 (+1.66%)
CGC   3.05 (-4.98%)
GE   160.91 (+1.42%)
DIS   113.97 (+1.80%)
AMC   4.34 (-0.46%)
PFE   25.80 (-2.97%)
PYPL   60.12 (-0.69%)
XOM   104.43 (-1.33%)
S&P 500   5,130.80 (-0.12%)
DOW   38,980.11 (-0.27%)
QQQ   445.22 (-0.09%)
AAPL   175.28 (-2.44%)
MSFT   415.51 (+0.00%)
META   499.65 (-0.53%)
GOOGL   133.71 (-2.50%)
AMZN   178.15 (-0.04%)
TSLA   189.13 (-6.67%)
NVDA   864.46 (+5.06%)
NIO   5.43 (-6.06%)
AMD   208.48 (+2.88%)
BABA   72.07 (-3.42%)
T   16.77 (-1.24%)
F   12.81 (+2.89%)
MU   96.73 (+1.66%)
CGC   3.05 (-4.98%)
GE   160.91 (+1.42%)
DIS   113.97 (+1.80%)
AMC   4.34 (-0.46%)
PFE   25.80 (-2.97%)
PYPL   60.12 (-0.69%)
XOM   104.43 (-1.33%)
TSE:IMV

IMV (IMV) Stock Price, News & Analysis

C$1.12
-0.02 (-1.75%)
(As of 04/28/2023)
Today's Range
C$1.07
C$1.13
50-Day Range
C$1.12
C$1.12
52-Week Range
C$0.62
C$15.90
Volume
15,761 shs
Average Volume
56,822 shs
Market Capitalization
C$13.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IMV stock logo

About IMV Stock (TSE:IMV)

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

IMV Stock Price History

IMV Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
YMCA celebrates 165 years
ISHARES VI PLC (IMV.AQ)
See More Headlines
Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
63
Year Founded
N/A

Profitability

Net Income
C$-37,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$23,000.00
Cash Flow
C$0.70 per share
Book Value
C($0.69) per share

Miscellaneous

Free Float
N/A
Market Cap
C$13.12 million
Optionable
Not Optionable
Beta
1.52
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Andrew Hall M.Sc.
    CEO & Director
  • Ms. Brittany Davison C.A. (Age 33)
    CPA, Chief Accounting Officer, Corp. Sec. & Director
    Comp: $207.9k
  • Dr. Jeremy R. Graff Ph.D. (Age 53)
    Chief Scientific Officer
    Comp: $558.1k
  • Delphine Davan
    Sr. Director of Communications & Investor Relations
  • Mr. Stephan Fiset M.B.A.
    M.Sc., VP of Clinical Research














IMV Stock Analysis - Frequently Asked Questions

Should I buy or sell IMV stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IMV in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IMV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMV, but not buy additional shares or sell existing shares.
View IMV analyst ratings
or view top-rated stocks.

How have IMV shares performed in 2024?

IMV's stock was trading at C$1.12 on January 1st, 2024. Since then, IMV shares have increased by 0.0% and is now trading at C$1.12.
View the best growth stocks for 2024 here
.

When did IMV's stock split?

Shares of IMV reverse split before market open on Monday, December 12th 2022. The 1-10 reverse split was announced on Monday, December 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of IMV own?
How do I buy shares of IMV?

Shares of IMV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:IMV) was last updated on 3/4/2024 by MarketBeat.com Staff